# A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment

> **NCT01497041** · PHASE2 · UNKNOWN · sponsor: **Korean South West Oncology Group** · enrollment: 35 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous
- Carcinoma, Large Cell

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT01497041
- **Lead sponsor:** Korean South West Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-02
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2011-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01497041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01497041, "A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01497041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*